Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Addresses Early, Asymptomatic Alzheimer’s In ‘Hugely Important’ Clinical Study Guidance

Executive Summary

The European Medicines Agency expects its revised guidance to facilitate the development of medicines to prevent and treat Alzheimer’s disease.

You may also be interested in...



Brexit Halts Work On 119 EMA Guidelines

The European Medicines Agency chief Guido Rasi is worried that if work on guidance development and revision stutters, "the whole system may suffer."

Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting

Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.

EU Regulators Make Finding & Using RWD Easier

Two new electronic catalogs of real-world data sources and studies offer an improved and more efficient service to help drug companies, regulators and researchers find adequate data sources to generate real-world evidence for regulatory purposes, says the European Medicines Agency.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel